"Digital twins are the future of medicine," Charles Fisher, founder and CEO of Unlearn AI said. "They basically replace our entire medical system; you basically turn medicine into a predictive science, you run experiments, and you optimize patients' treatments."
Part of a broader phenomenon known as 'digital twins for health,' the use of digital twins to advance drug development is one of the most promising uses of the technology. While still early, data from startups and drug companies suggest digital twin simulation can speed up drug development and shave costs, thus providing a clear life-saving and economic incentive.
Sean McClain, founder and CEO of Absci, is similarly bullish about decreasing the approval time for new drugs, increasing success rates, and lowering costs through the use of digital twins combined with generative AI.
A digital twin can simulate on the computer the structure of an organ, such as a lung, heart, or brain; the areas of a cell where drugs can bind to treat disease; or the entire state of health of a patient in a clinical trial.
[
Collection
]
[
|
...
]